Campaign encourages the use of low-dose aspirin to help reduce the risk of preeclampsia and the complications that come with it.
The Preeclampsia Foundation partnered with Patients & Purpose to launch GAP—SPIRIN, an educational campaign that aims to help prevent the hypertensive disorder through the use of low-dose aspirin. It also aims to close the maternal health equity gap.1 Preeclampsia develops in 5-8% of all pregnancies, but it is 60% more likely to occur amongst Black expectant mothers. The launch announcement came on January 23rd, Maternal Health Awareness Day.
"The stark reality is that Black women face so many barriers to a healthy pregnancy—limited access to healthcare, decreased time during doctor visits, and symptoms and concerns that often get overlooked," explained Dr. Cornelia Graves, a maternal-fetal medicine subspecialist with Tennessee Maternal Fetal Medicine and member of the Preeclampsia Foundation's Medical Advisory Board in the release. "The healthcare community must respond by making sure that Black women are heard, informed, and receive low-dose aspirin prophylaxis for preeclampsia when appropriate to improve outcomes."
"That's where an effort like GAP—SPIRIN comes in," said Dina Peck, chief creative officer of Patients & Purpose, in the press release. "We partnered with the Preeclampsia Foundation to help close the diagnosis and prevention equity gap in preeclampsia by educating healthcare providers and their patients about low-dose aspirin."
GAP—SPIRIN’s initial launch provides 100 obstetric HCPs in high-risk communities across New York City with resources and educational materials about the use of aspirin as a preventative treatment. A low-dose aspirin regimen helps reduce the risk of preeclampsia and its complications, like organ damage, HELLP syndrome, placenta abruption, stroke, preterm and still birth. The participating offices are encouraged to submit their thoughts on current practices and pledge to do their part to help close the gap in maternal health.
"The Preeclampsia Foundation is focused on promoting solutions to care for Black women affected by hypertensive disorders of pregnancy, not just restating the problem," said Preeclampsia Foundation director of communications and engagement Laney Poye. "We have the power to close the gap in maternal health by taking proactive action. That's why we are taking a multi-level approach that includes national, local and individual action to address preeclampsia and its impact on Black women and birthing people."
In mid-September 2024, the Preeclampsia Foundation announced a partnership with the International Society for the Study of Hypertension in Pregnancy and Society for Maternal-Fetal Medicine to give patients a resource to manage and reduce their long-term heart risk caused by hypertensive disorders of pregnancy. The updated “My Health Beyond Pregnancy” is a free downloadable worksheet where patients can organize their long-term care plan. At the time of the announcement, Preeclampsia Foundation CEO Eleni Tsigas said that patients often know about their long-term risk, but don’t know what the next steps are.
“Preeclampsia is a serious condition that can arise during and after pregnancy. It is imperative for patients to engage in dialogue with their healthcare providers regarding the factors that contribute to the risk, appropriate management strategies, and the enduring health implications. Through the employment of this tool, our objective is to assist patients in managing this critical medical issue during pregnancy, with an eye toward promoting their future well-being,” Dr. Cynthia Gyamfi-Bannerman, SMFM president, said in the release.
Preeclampsia Foundation Launches GAP--SPIRIN: a creative intervention for Black maternal health. Omnicom Health Group. January 23, 2025. Accessed January 24, 2025. https://www.prnewswire.com/news-releases/preeclampsia-foundation-launches-gapspirin-a-creative-intervention-for-black-maternal-health-302358047.html
Preeclampsia Foundation and partners launch updated “My Health Beyond Pregnancy” resource for tracking long-term heart health impact. The Preeclampsia Foundation. September 17, 2024. Accessed January 24, 2025. https://www.preeclampsia.org/the-news/health-information/preeclampsia-foundation-and-partners-launch-updated-my-health-beyond-pregnancy-resource-for-long-term-health
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.